3-Aminobenzamide does not alter DNA repair in human fibroblasts through modulation of deoxynucleoside triphosphate pools.
3-Aminobenzamide does not deplete cellular purine deoxynucleoside triphosphate pools as do the structurally-related ribonucleotide reductase inhibitors, the hydroxy- and amino-substituted benzohydroxamic acids. Thus, the previously reported ability of 3-aminobenzamide to inhibit de novo synthesis of DNA purines does not appear to be due to a direct effect on pools via inhibition of ribonucleotide reductase. The enhancement rather than inhibition by 3-aminobenzamide of DNA repair in the present studies, however, leaves open the possibility that pool modulation may play a role in cell systems where repair inhibitory effects are seen.
D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology*; D002478:Cells, Cultured; D004260:DNA Repair / Q000187:drug effects*; D003854:Deoxyribonucleotides / Q000378:metabolism*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D008297:Male; D008741:Methyl Methanesulfonate / Q000494:pharmacology; D012867:Skin / Q000378:metabolism
D000970:Antineoplastic Agents; D001549:Benzamides; D003854:Deoxyribonucleotides; D006877:Hydroxamic Acids; C036110:3,4,5-trihydroxybenzohydroxamic acid; C025160:3-aminobenzamide; D008741:Methyl Methanesulfonate; D006918:Hydroxyurea